ManufacturingProcess Development and Manufacturing
Repertoire’s proprietary process development and manufacturing capabilities enable us to create the Right Medicine for the Right Patient at Right Dose and Potency – and do it at scale. Our optimized manufacturing yields younger, non-exhausted T cells, high numbers of reactive T cells, and multiple T cell clones targeting multiple antigens. Each production run generates a sufficient supply of drug product for multiple dosing of the patient.
We began our first trial in 2019 with a pan-tumor antigen repertoire found in numerous solid tumor types using our first-generation manufacturing process. We have recently introduced a second-generation manufacturing process, which has substantially increased the number of reactive T cells and number of younger phenotypes.
Our process development and manufacturing infrastructure are in place today.
|Properties||Repertoire Immune Medicines||Others (e.g., CAR-T)|
|Requires Genetic Engineering||No||Yes|
|Cytokines Attached to T Cell||Yes||No|
|# of Clones||Multiple||1|